Innate Pharma SA
IPHA · XNASCIK 1598599fmd_1P7P9FRGRZ3R6XKGKAX67SQGV3Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Dec 31, 2025, 15 periods
Latest annual · FY2025
Millions- Total revenues
- 9
- Operating income
- (54)
- Net income
- (49)
- Free cash flow
- (53)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -46.2%
- Revenue, 5 yearsFY2020 to FY2025
- -33.6%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Innate Pharma SA (IPHA) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | €9 million | €20.1 million | -55.2% | 20-F 2026-04-01 · proof |
| Operating income | -€54 million | -€51.6 million | 20-F 2026-04-01 · proof | |
| Net income | -€49.2 million | -€49.5 million | 20-F 2026-04-01 · proof | |
| Cash from operating activities | -€52.8 million | -€6.9 million | 20-F 2026-04-01 · proof | |
| Free cash flow | -€52.9 million | -€7.3 million | 20-F 2026-04-01 · proof | |
| Total assets | €62.7 million | €111.1 million | -43.5% | 20-F 2026-04-01 · proof |
| Total liabilities | €84.4 million | €102.2 million | -17.4% | 20-F 2026-04-01 · proof |
| Cash and cash equivalents | €28.1 million | €66.4 million | -57.7% | 20-F 2026-04-01 · proof |
- What was Innate Pharma SA (IPHA)'s revenue in fiscal 2025?
- Innate Pharma SA (IPHA) reported revenue of €9 million for fiscal 2025 (the year ended Dec 31, 2025), against €20.1 million the year before (-55.2%). Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
- What was Innate Pharma SA (IPHA)'s operating income in fiscal 2025?
- Innate Pharma SA (IPHA) reported operating income of -€54 million for fiscal 2025 (the year ended Dec 31, 2025), against -€51.6 million the year before. Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
- What was Innate Pharma SA (IPHA)'s net income in fiscal 2025?
- Innate Pharma SA (IPHA) reported net income of -€49.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -€49.5 million the year before. Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
- What was Innate Pharma SA (IPHA)'s cash from operating activities in fiscal 2025?
- Innate Pharma SA (IPHA) reported cash from operating activities of -€52.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -€6.9 million the year before. Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
- What was Innate Pharma SA (IPHA)'s free cash flow in fiscal 2025?
- Innate Pharma SA (IPHA) reported free cash flow of -€52.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -€7.3 million the year before. Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
- What are Innate Pharma SA (IPHA)'s total assets?
- As of Dec 31, 2025, Innate Pharma SA (IPHA) reported total assets of €62.7 million, against €111.1 million a year earlier (-43.5%). Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
- What are Innate Pharma SA (IPHA)'s total liabilities?
- As of Dec 31, 2025, Innate Pharma SA (IPHA) reported total liabilities of €84.4 million, against €102.2 million a year earlier (-17.4%). Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
- What are Innate Pharma SA (IPHA)'s cash and cash equivalents?
- As of Dec 31, 2025, Innate Pharma SA (IPHA) reported cash and cash equivalents of €28.1 million, against €66.4 million a year earlier (-57.7%). Source: the 20-F filed with the SEC on Apr 1, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:IPHA&period_type=annual&limit=5"Information only, not investment advice.